JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
Atea showcased its Phase III HCV programme at JPM for bemnifosbuvir/ruzasvir, positioning the regimen for test-and-treat adoption in ~1,800 patients. C-BEYOND data are expected mid-2026, with C-FORWARD results by year-end 2026.
